8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Mar 16, 2026·SEC
Soleno Therapeutics, Inc.(SLNO)Earnings, Financials & Key Ratios
SLNO•NASDAQ
$52.95
$2.76B mkt cap·135.8× P/E·Price updated May 7, 2026
AboutSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Show more
- Revenue$190M
- EBITDA$17M+109.1%
- Net Income$21M+111.9%
- EPS (Diluted)0.39+108.9%
- Gross Margin98.58%
- EBITDA Margin8.91%
- Operating Margin7.85%
- Net Margin10.97%
- ROE6.01%+106.9%
- ROIC3.78%+102.7%
- Debt/Equity0.01-97.2%
- Interest Coverage4.81+100.6%
SLNO Key Insights
Soleno Therapeutics, Inc. (SLNO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 24.5% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy 5Y average net margin of 11.0%
✗Weaknesses
- ✗Shares diluted 35.2% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SLNO Price & Volume
Soleno Therapeutics, Inc. (SLNO) stock price & volume — 10-year historical chart
Loading chart...
SLNO Growth Metrics
Soleno Therapeutics, Inc. (SLNO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years85.84%
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM111.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM105.32%
Return on Capital
10 Years-83.4%
5 Years-59.56%
3 Years-39.41%
Last Year3.67%
SLNO Recent Earnings
Soleno Therapeutics, Inc. (SLNO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 1/12 qtrs (33%)
Q1 2026Latest
Feb 25, 2026EPS
$0.80
Est $0.64
+25.0%
Revenue
$92M
Est $89M
+3.4%
Q4 2025
Nov 4, 2025EPS
$0.47
Est $0.06
+717.4%
Revenue
$66M
Est $89M
-25.4%
Q3 2025
Aug 6, 2025EPS
$0.09
Est $0.53
+83.0%
Revenue
$33M
Est $39M
-17.0%
Q2 2025
May 7, 2025EPS
$0.95
Est $1.14
+16.7%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.80vs $0.64+25.0% | $92Mvs $89M+3.4% |
| Q4 2025 | Nov 4, 2025 | $0.47vs $0.06+717.4% | $66Mvs $89M-25.4% |
| Q3 2025 | Aug 6, 2025 | $0.09vs $0.53+83.0% | $33Mvs $39M-17.0% |
| Q2 2025 | May 7, 2025 | $0.95vs $1.14+16.7% | — |
Based on last 12 quarters of dataView full earnings history →
SLNO Peer Comparison
Soleno Therapeutics, Inc. (SLNO) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 RYTM | 6.59B | 96.23 | -30.94 | 45.83% | -93.84% | -204.35% | 1.77 | |
 MDGL | 12.27B | 534.86 | -41.62 | 432.05% | -27.32% | -50.15% | 0.59 | |
 PTCT | 5.35B | 64.49 | 8.29 | 114.51% | -22.58% | |||
 ANAB | 2.89B | 66.96 | -145.57 | 157.01% | -5.64% | -24.49% | 0.38 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 |
Compare SLNO vs Peers
Soleno Therapeutics, Inc. (SLNO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLNO Income Statement
Soleno Therapeutics, Inc. (SLNO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | -1.55B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 190.41M |
| Revenue Growth % | -107145.41% | 100% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.61M | 1.92M | 2.3M | 2.19M | 0 | 0 | 0 | 0 | 2.7M |
| COGS % of Revenue | -0.1% | - | - | - | - | - | - | - | 1.42% |
| Gross Profit | -1.55B▲ 0% | -1.92M▲ 99.9% | -2.3M▼ 19.7% | -2.19M▲ 4.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 187.71M▲ 0% |
| Gross Margin % | 100.1% | - | - | - | - | - | - | - | 98.58% |
| Gross Profit Growth % | -2656540.69% | 99.88% | -19.7% | 4.48% | 100% | - | - | - | - |
| Operating Expenses | 9.68M | 13.73M | 20.9M | 29.75M | 31.53M | 24.4M | 41.38M | 187.67M | 172.75M |
| OpEx % of Revenue | -0.62% | - | - | - | - | - | - | - | 90.73% |
| Selling, General & Admin | 6.61M | 6.56M | 4.63M | 6.56M | 10.81M | 9.84M | 13.48M | 105.86M | 132.13M |
| SG&A % of Revenue | -0.43% | - | - | - | - | - | - | - | 69.39% |
| Research & Development | 3.07M | 7.18M | 16.27M | 23.19M | 21.45M | 15.27M | 25.19M | 78.57M | 40.63M |
| R&D % of Revenue | -0.2% | - | - | - | - | - | - | - | 21.34% |
| Other Operating Expenses | -585.95K | 6K | 0 | 0 | -731K | -712K | 2.71M | 3.24M | 0 |
| Operating Income | -12.17M▲ 0% | -14.3M▼ 17.5% | -23.2M▼ 62.2% | -31.95M▼ 37.7% | -31.53M▲ 1.3% | -24.4M▲ 22.6% | -41.38M▼ 69.6% | -187.67M▼ 353.5% | 14.95M▲ 108.0% |
| Operating Margin % | 0.78% | - | - | - | - | - | - | - | 7.85% |
| Operating Income Growth % | 10.57% | -17.5% | -62.21% | -37.73% | 1.32% | 22.62% | -69.63% | -353.49% | 107.97% |
| EBITDA | -10.56M | -12.38M | -20.9M | -29.75M | -29.57M | -22.43M | -39.43M | -185.68M | 16.97M |
| EBITDA Margin % | 0.68% | - | - | - | - | - | - | - | 8.91% |
| EBITDA Growth % | 22.3% | -17.25% | -68.79% | -42.37% | 0.64% | 24.12% | -75.75% | -370.97% | 109.14% |
| D&A (Non-Cash Add-back) | 1.61M | 1.92M | 2.3M | 2.19M | 1.96M | 1.96M | 1.96M | 1.99M | 2.02M |
| EBIT | -13.44M | -13.73M | -30.77M | -24.64M | -32.26M | -24.07M | -38.99M | -175.62M | 26.37M |
| Net Interest Income | 0 | 0 | 154K | 13K | 110K | 300K | 2.58M | 11.82M | 11.48M |
| Interest Income | 0 | 0 | 154K | 13K | 110K | 300K | 2.58M | 12.05M | 16.95M |
| Interest Expense | 0 | 62K | 0 | 0 | 0 | 0 | 0 | 231K | 5.48M |
| Other Income/Expense | -1.27M | 2.46M | -7.58M | 7.31M | 618K | 330K | 2.4M | 11.82M | 5.94M |
| Pretax Income | -13.72M▲ 0% | -11.84M▲ 13.7% | -30.77M▼ 159.9% | -24.64M▲ 19.9% | -30.91M▼ 25.5% | -24.07M▲ 22.1% | -38.99M▼ 62.0% | -175.85M▼ 351.0% | 20.89M▲ 111.9% |
| Pretax Margin % | 0.88% | - | - | - | - | - | - | - | 10.97% |
| Income Tax | -1.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 12.03% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -15.67M▲ 0% | -13.34M▲ 14.9% | -30.77M▼ 130.8% | -24.64M▲ 19.9% | -30.91M▼ 25.5% | -24.07M▲ 22.1% | -38.99M▼ 62.0% | -175.85M▼ 351.0% | 20.89M▲ 111.9% |
| Net Margin % | 1.01% | - | - | - | - | - | - | - | 10.97% |
| Net Income Growth % | -29.86% | 14.89% | -130.78% | 19.94% | -25.45% | 22.14% | -62% | -351.04% | 111.88% |
| Net Income (Continuing) | -11.79M | -11.84M | -30.77M | -24.64M | -30.91M | -24.07M | -38.99M | -175.85M | 20.89M |
| Discontinued Operations | -3.59M | -1.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -26.18▲ 0% | -9.54▲ 63.6% | -15.78▼ 65.4% | -3.68▲ 76.7% | -5.81▼ 57.9% | -2.87▲ 50.6% | -2.36▲ 17.8% | -4.38▼ 85.6% | 0.39▲ 108.9% |
| EPS Growth % | 55.13% | 63.56% | -65.41% | 76.68% | -57.88% | 50.6% | 17.77% | -85.59% | 108.9% |
| EPS (Basic) | -26.18 | -9.54 | -15.78 | -3.68 | -5.81 | -2.87 | -2.36 | -4.38 | 0.41 |
| Diluted Shares Outstanding | 598.52K | 1.4M | 2.28M | 4.17M | 5.32M | 8.4M | 16.49M | 40.18M | 54.33M |
| Basic Shares Outstanding | 598.52K | 1.4M | 2.28M | 4.17M | 5.32M | 8.4M | 16.49M | 40.18M | 53.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
SLNO Balance Sheet
Soleno Therapeutics, Inc. (SLNO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.99M | 24.67M | 21.14M | 50.24M | 22.42M | 15.65M | 171.36M | 293.89M | 355.81M |
| Cash & Short-Term Investments | 17.1M | 24.08M | 20.73M | 49.22M | 21.3M | 14.6M | 169.68M | 291.44M | 305.47M |
| Cash Only | 17.1M | 23.1M | 20.73M | 49.22M | 21.3M | 14.6M | 169.68M | 87.93M | 70.11M |
| Short-Term Investments | 0 | 978K | 0 | 0 | 0 | 0 | 0 | 203.51M | 235.37M |
| Accounts Receivable | 0 | 64K | 0 | 0 | 0 | 0 | 0 | 0 | 28.21M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | 54.07 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.02M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | 2.03K |
| Other Current Assets | 551K | 0 | 0 | 0 | 0 | 1.04M | 1.68M | 2.45M | 7.11M |
| Total Non-Current Assets | 21.03M | 18.48M | 17.03M | 14.74M | 13.13M | 10.85M | 9.33M | 37.08M | 208.02M |
| Property, Plant & Equipment | 22.89K | 12K | 444K | 158K | 454K | 157K | 419K | 2.98M | 2.38M |
| Fixed Asset Turnover | -67861.13x | - | - | - | - | - | - | - | 80.14x |
| Goodwill | 125.53K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 20.41M | 18.47M | 16.52M | 14.58M | 12.64M | 10.69M | 8.75M | 6.8M | 4.86M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27.21M | 0 |
| Other Non-Current Assets | 591.92K | 0 | 59K | 0 | 40K | 0 | 165K | 83K | 200.78M |
| Total Assets | 39.02M▲ 0% | 43.15M▲ 10.6% | 38.17M▼ 11.5% | 64.98M▲ 70.2% | 35.55M▼ 45.3% | 26.5M▼ 25.5% | 180.69M▲ 581.9% | 330.97M▲ 83.2% | 563.83M▲ 70.4% |
| Asset Turnover | -39.80x | - | - | - | - | - | - | - | 0.34x |
| Asset Growth % | 601.22% | 10.58% | -11.54% | 70.23% | -45.29% | -25.47% | 581.93% | 83.17% | 70.36% |
| Total Current Liabilities | 1.73M | 1.88M | 4.96M | 8.62M | 8.01M | 7.31M | 11.51M | 18.75M | 61.36M |
| Accounts Payable | 633K | 934K | 2M | 3.49M | 3.25M | 1.78M | 3.15M | 8.88M | 12.44M |
| Days Payables Outstanding | 143.42 | 177.65 | 317.01 | 580.44 | - | - | - | - | 1.68K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 726K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 127K | 623K | 665K | 1.2M | 1.05M | 2.16M | 4.95M | 9.34M | 48.2M |
| Current Ratio | 10.38x | 13.14x | 4.26x | 5.83x | 2.80x | 2.14x | 14.89x | 15.68x | 5.80x |
| Quick Ratio | 10.38x | 13.14x | 4.26x | 5.83x | 2.80x | 2.14x | 14.89x | 15.68x | 5.55x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | 404.07 |
| Total Non-Current Liabilities | 10.75M | 10.86M | 18.26M | 10.82M | 9.75M | 8.84M | 11.68M | 67.11M | 52.35M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49.83M | 1.96M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 175K | 0 | 130K | 2.47M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10.47M | 10.86M | 18.26M | 10.82M | 9.58M | 8.84M | 11.55M | 14.81M | 50.39M |
| Total Liabilities | 12.49M | 12.74M | 23.23M | 19.43M | 17.76M | 16.15M | 23.18M | 85.86M | 113.72M |
| Total Debt | 0 | 0 | 305K | 139K | 457K | 155K | 403K | 52.83M | 2.69M |
| Net Debt | -17.1M | -23.1M | -20.43M | -49.09M | -20.85M | -14.45M | -169.28M | -35.1M | -67.42M |
| Debt / Equity | - | - | 0.02x | 0.00x | 0.03x | 0.01x | 0.00x | 0.22x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -3.97x |
| Interest Coverage | - | -221.52x | - | - | - | - | - | -760.26x | 4.81x |
| Total Equity | 26.53M▲ 0% | 30.41M▲ 14.6% | 14.95M▼ 50.9% | 45.55M▲ 204.7% | 17.79M▼ 60.9% | 10.35M▼ 41.8% | 157.51M▲ 1422.1% | 245.11M▲ 55.6% | 450.12M▲ 83.6% |
| Equity Growth % | 672.44% | 14.62% | -50.85% | 204.72% | -60.93% | -41.84% | 1422.1% | 55.62% | 83.64% |
| Book Value per Share | 44.33 | 21.75 | 6.57 | 10.91 | 3.35 | 1.23 | 9.55 | 6.10 | 8.28 |
| Total Shareholders' Equity | 26.53M | 30.41M | 14.95M | 45.55M | 17.79M | 10.35M | 157.51M | 245.11M | 450.12M |
| Common Stock | 19.24K | 32K | 45K | 80K | 80K | 8K | 32K | 46K | 52K |
| Retained Earnings | -113.98M | -127.03M | -157.81M | -182.44M | -213.35M | -237.42M | -276.41M | -452.26M | -431.37M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -73.65K | -93K | 0 | 0 | 0 | 0 | 0 | 361K | 415K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLNO Cash Flow Statement
Soleno Therapeutics, Inc. (SLNO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.95M | -11.68M | -17.38M | -25.22M | -27.77M | -20.78M | -24.94M | -69.1M | 46.8M |
| Operating CF Margin % | 0.64% | - | - | - | - | - | - | - | 24.58% |
| Operating CF Growth % | 26.29% | -17.42% | -48.72% | -45.17% | -10.09% | 25.17% | -20.01% | -177.05% | 167.73% |
| Net Income | -12.07M | -11.84M | -30.77M | -24.64M | -30.91M | -24.07M | -38.99M | -175.85M | 20.89M |
| Depreciation & Amortization | 1.61M | 1.96M | 1.96M | 1.95M | 1.96M | 1.96M | 1.96M | 1.99M | 2.02M |
| Stock-Based Compensation | 880.03K | 988K | 825K | 1.5M | 3.28M | 2.53M | 5.95M | 99.96M | 45.85M |
| Deferred Taxes | -1.65M | -3.88M | 6.96M | -11.64M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.31M | 1M | 1.15M | 4.62M | -951K | -452K | 3.22M | -1.21M | 2.68M |
| Working Capital Changes | -24.07K | 82K | 2.5M | 2.98M | -1.15M | -756K | 2.93M | 6.02M | -24.63M |
| Change in Receivables | 0 | -64K | 64K | 0 | 0 | 0 | 0 | 0 | -28.21M |
| Change in Inventory | 0 | 0 | -64K | 0 | 0 | 0 | 0 | 0 | -14.03M |
| Change in Payables | 190.63K | 249K | 1.06M | 1.49M | -235K | -1.48M | 1.37M | 5.67M | 3.61M |
| Cash from Investing | 378.78K | -180K | 528K | -7K | -22K | -13K | 0 | -225.68M | -201.78M |
| Capital Expenditures | -2.57K | -8K | -21K | -7K | -22K | -13K | 0 | -218K | -73K |
| CapEx % of Revenue | -0% | - | - | - | - | - | - | - | 0.04% |
| Acquisitions | -572.59K | 0 | 500K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 953.94K | -172K | 49K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 23.94M | 17.83M | 14.48M | 53.72M | -128K | 14.09M | 180.02M | 213.03M | 137.16M |
| Debt Issued (Net) | 0 | 0 | -2K | -17K | -8K | 0 | 0 | 49.89M | 0 |
| Equity Issued (Net) | 25.01M | 16.3M | 14.48M | 53.72M | 0 | 14.11M | 137.86M | 148.96M | 137.96M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -100.15M |
| Other Financing | -838K | 1.52M | 0 | 17K | -120K | -16K | 42.16M | 14.18M | -803K |
| Net Change in Cash | 14.37M▲ 0% | 5.96M▼ 58.5% | -2.37M▼ 139.7% | 28.49M▲ 1304.2% | -27.92M▼ 198.0% | -6.7M▲ 76.0% | 155.08M▲ 2413.9% | -81.75M▼ 152.7% | -17.82M▲ 78.2% |
| Free Cash Flow | -9.95M▲ 0% | -11.69M▼ 17.5% | -17.4M▼ 48.8% | -25.23M▼ 45.0% | -27.79M▼ 10.2% | -20.79M▲ 25.2% | -24.94M▼ 19.9% | -69.31M▼ 177.9% | 46.73M▲ 167.4% |
| FCF Margin % | 0.64% | - | - | - | - | - | - | - | 24.54% |
| FCF Growth % | 26.48% | -17.47% | -48.8% | -45.04% | -10.15% | 25.18% | -19.94% | -177.92% | 167.41% |
| FCF per Share | -16.63 | -8.36 | -7.64 | -6.04 | -5.23 | -2.48 | -1.51 | -1.73 | 0.86 |
| FCF Conversion (FCF/Net Income) | 0.64x | 0.88x | 0.56x | 1.02x | 0.90x | 0.86x | 0.64x | 0.39x | 2.24x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 800 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLNO Key Ratios
Soleno Therapeutics, Inc. (SLNO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -362.37% | -104.55% | -46.83% | -135.69% | -81.46% | -97.6% | -171.05% | -46.45% | -87.35% | 6.01% |
| Return on Invested Capital (ROIC) | -1439.31% | -179.97% | -128.07% | -1898.28% | - | - | - | - | -142% | 3.78% |
| Gross Margin | -4.03% | 100.1% | - | - | - | - | - | - | - | 98.58% |
| Net Margin | -831.63% | 1.01% | - | - | - | - | - | - | - | 10.97% |
| Debt / Equity | - | - | - | 0.02x | 0.00x | 0.03x | 0.01x | 0.00x | 0.22x | 0.01x |
| Interest Coverage | - | - | -221.52x | - | - | - | - | - | -760.26x | 4.81x |
| FCF Conversion | 1.12x | 0.64x | 0.88x | 0.56x | 1.02x | 0.90x | 0.86x | 0.64x | 0.39x | 2.24x |
| Revenue Growth | 274.34% | -107145.41% | 100% | - | - | - | - | - | - | - |
SLNO SEC Filings & Documents
Soleno Therapeutics, Inc. (SLNO) SEC filings — annual & quarterly reports (10-K, 10-Q)
SLNO Frequently Asked Questions
Soleno Therapeutics, Inc. (SLNO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Soleno Therapeutics, Inc. (SLNO) reported $190.4M in revenue for fiscal year 2025.
Soleno Therapeutics, Inc. (SLNO) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Soleno Therapeutics, Inc. (SLNO) is profitable, generating $20.9M in net income for fiscal year 2025 (11.0% net margin).
Dividend & Returns
Soleno Therapeutics, Inc. (SLNO) has a return on equity (ROE) of 6.0%. This is below average, suggesting room for improvement.
Soleno Therapeutics, Inc. (SLNO) generated $46.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More SLNO
Soleno Therapeutics, Inc. (SLNO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates